The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: A systematic review

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 477-487

  Sohn, Winnie ^a   Simiens, Mary Ann ^a   Jaeger, Kelly ^a   Hutton, Shauna ^a   Jang, Graham ^a  

^a AMGEN INC   (United States)

Author keywords

advanced cancer patients; bone metastases; denosumab; pharmacodynamics; pharmacokinetics

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DENOSUMAB; PLACEBO; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

ADVANCED CANCER; AREA UNDER THE CURVE; BODY WEIGHT; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CREATININE URINE LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SYSTEMATIC REVIEW; ADULT; BONE NEOPLASMS; METABOLISM; NEOPLASMS; PATHOLOGY; SECONDARY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; DENOSUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; RANK LIGAND;

EID: 84906504179     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12355     Document Type: Review

References (33)

1. Coleman RE,. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249. (Pubitemid 44703797)
2. Coleman RE, Plunkett TA, Rubens RD,. Clinical features and prognosis of bone metastases. In: Textbook of Bone Metastases, ed., Coleman RE,. Chichester: John Wiley and Sons, Ltd, 2006; 65-75.
3. Theriault RL,. Biology of bone metastases. Cancer Control 2012; 19: 92-101.
4. Coleman RE,. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer treatment reviews 2001; 27: 165-176. (Pubitemid 32452017)
5. Kanis JA, McCloskey EV, Taube T, O'Rourke N,. Rationale for the use of bisphosphonates in bone metastases. Bone 1991; 12 (Suppl. 1): S13-18.
6. Tanaka S, Nakamura K, Takahasi N, Suda T,. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005; 208: 30-49. (Pubitemid 41746383)
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T,. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-3602.
8. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE,. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89: 2031-2037. (Pubitemid 38030899)
9. Roodman GD, Dougall WC,. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008; 34: 92-101. (Pubitemid 351181016)
10. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ,. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005; 146: 3235-3243. (Pubitemid 41058092)
11. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, Lipton A,. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20: 850-856. (Pubitemid 34111395)
12. Lipton A, Costa L, Ali SM, Demers LM,. Bone markers in the management of metastatic bone disease. Cancer Treat Rev 2001; 27: 181-185. (Pubitemid 32452019)
13. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD,. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20: 2353-2359. (Pubitemid 34441663)
14. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM,. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066. (Pubitemid 41110556)
15. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A,. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
16. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C,. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
17. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H,. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
18. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ,. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228. (Pubitemid 43342512)
19. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S,. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 4431-4437. (Pubitemid 350013849)
20. Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Perez-Ruixo JJ,. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 2012; 51: 247-260.
21. Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Perez-Ruixo JJ,. Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res 2012; 18: 2648-2657.
22. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ,. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-892. (Pubitemid 36125828)
23. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S,. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
24. Chen D, Sarikaya NA, Gunn H, Martin SW, Young JD,. ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin Chem 2001; 47: 747-749. (Pubitemid 32275821)
25. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR,. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251-1258. (Pubitemid 23000964)
26. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332. (Pubitemid 351738156)
27. Tabrizi MA, Roskos LK,. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12: 540-547. (Pubitemid 47031663)
28. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633-659.
29. Waldmann TA,. Disorders of immunoglobulin metabolism. N Engl J Med 1969; 281: 1170-1177.
30. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
31. Wileman T, Harding C, Stahl P,. Receptor-mediated endocytosis. Biochem J 1985; 232: 1-14. (Pubitemid 16202384)
32. Thurmann PA, Sonnenburg C, Valentova K, Gregora E, Freischlager F, Lissner R,. Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukaemia or multiple myeloma. Eur J Clin Pharmacol 2001; 57: 235-241. (Pubitemid 32662468)
33. XGEVA® (Denosumab) Package Insert. Thousand Oaks, CA: Amgen, Inc., 2012.